ZVRA — Zevra Therapeutics, Inc.
ZVRA dilution and offerings
- Float: 55.5M shares
🔔 Alert me if ZVRA files an offering or S-3
$10.26+1.58%
Last close: · regular session
Pre-market $10.51 +2.44% ·
Last 60 sessions
Float: 55.5M shares. Latest SEC filing: 8-K on Nov 3, 2026. ZVRA closed at $10.26 (+1.58%) on Nov 3, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ZVRA in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 59
- Website: https://zevra.com
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Latest SEC filings for ZVRA
Latest ZVRA news
- Zevra anticipates filing MIPLYFFA sNDA in Q1 2027 as CHMP opinion remains expected in Q4 Read article
- Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates Read article
- Zevra Therapeutics, Inc. GAAP EPS of $0.26 beats by $0.11, revenue of $37.8M beats by $0.39M Read article
- Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.